Compare Rush Street Interactive Inc (RSI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rush Street Interactive Inc vs Recursion Pharmaceuticals Inc — how do they compare? Rush Street Interactive Inc trades at $24.54 (market cap $2.91B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Rush Street Interactive Inc is the larger of the two by market cap, and Rush Street Interactive Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RSI | RXRX | |
|---|---|---|
Market Cap | $2.91B | $1.81B |
Sector | Technology | Health |
52-Week High | $34.52 | $6.79 |
52-Week Low | $15.89 | $2.84 |
Enterprise Value | $2.57B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rush Street Interactive (RSI) trades at $25.08, up 1.46% today, with a bearish technical signal but strong analyst support. The company reported record Q2 2026 revenue of $393.8 million, up 46% year-over-year, and raised full-year guidance. Despite a high P/E ratio of 81.13, profitability metrics like a 20.72% ROE and recent earnings beats signal operational strength. Key resistance sits at $26, with support near $24.
The outlook is positive driven by revenue growth and market expansion, but high valuation and mixed technicals pose risks. Analyst consensus is bullish with a $34.75 price target, though regulatory pressures in the gaming sector remain a concern. The stock offers growth potential but requires monitoring of execution and market sentiment.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
